Kenneth Krohn, Ph.D.

  • Professor of Diagnostic Radiology, School of Medicine


Dr. Kenneth A. Krohn recently joined the Center for Radiochemistry Research at OHSU to help in the development of a translational radiochemistry program and facility in support of nuclear imaging. He received his PhD in physical chemistry from the University of California, Davis and completed two years of post-doctoral training under Prof. Michael Welch at Washington University.  He was recruited to UC Davis as Assistant Professor of Radiology when they opened the new medical school. He was served as the Associate Director for Life Sciences at Crocker Nuclear Lab. Dr. Krohn spent sabbatical time at Cross Canter Institute, University of Alberta and at Donner Lab, University of California, Berkeley working in the laboratory of Prof. Tom Budinger. He was recruited to University of Washington in 1981 to start a new research program in positron emission tomography (PET). He was a Professor in the Departments of Radiology and Radiation Oncology and Adjunct Professor of Chemistry. Dr. Krohn directed a program project in PET imaging of cancer and its response to therapy for nearly three decades and transitioned to Emeritus Professor at UW in 2015. 

The UW program was effective in developing and translating several F-18 radiopharmaceuticals to multicenter clinical trials, agents such as fluoromisonidazole, fluorothymidine, and fluoroestradiol. The program provided training for physician scientists who are now important participants in molecular imaging worldwide, individuals such as Michael Graham, Tony Shields, John M. Hoffman, Francis Ali-Osman, David Mankoff and Janet Eary. Dr. Krohn has also mentored several graduate students. Professor Krohn co-authored over 300 peer-reviewed articles regarding biomedical radiochemistry and imaging. He has reviewed for numerous federal and international granting agencies and is a patentee in field. Dr. Krohn is on the editorial boards of Journal of Nuclear Medicine and Cancer Research and reviews manuscripts for numerous professional journals. His professional awards include NDEA fellow, AAAS Fellow and the Paul C. Aebersold award. His biomedical research program has focused on the biology of hypoxia, methods for imaging hypoxia and the importance of hypoxia in response to therapy. At OHSU Dr. Krohn’s role is to mentor young physician scientists in molecular imaging.

Education and training

    • B.A., 1966, Andrews University
    • Ph.D., 1971, Univeristy of California

Memberships and associations:

  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American Chemical Society
  • American Society of Clinical Oncology
  • Radiation Research Society
  • Society of Nuclear Medicine and Molecular Imaging
  • Society of Radiopharmaceutical Sciences

Areas of interest

  • Kinetic Analysis of Reaction Rates Using Radioisotopes
  • Kinetic Analysis of Imaging Data
  • Development of New Radiopharmaceuticals
  • The Use of Imaging to Study the Biology of Hypoxia
  • The Use of PET Radiopharmaceuticals for More Efficient Cinical Trials of New Cancer Treatments

Honors and awards

  • CRC Chemistry Achievement Award, 1962-63
  • NDEA Title IV Fellow, 1966-68
  • American Men and Women of Science; Sigma Xi; Who’s Who in America; Fellow, AAAS, 1992
  • Paul C. Aebersold Award for Outstanding Achievement in Basic Science Applied to Nuclear Medicine, SNM, 1996
  • Inaugural Michael J. Welch Lecture, Siteman Cancer Center, 2012
  • Distinguished Scientist Award, Western Society of Nuclear Medicine and Molecular Imaging, 2015


Selected publications

  • Gersberg R, Krohn K, Peek NF, Goldman CR: Denitrification studies with 13N-labeled nitrate. Science 192(4245):1229-1231, 1976. PMID: 17771756
  • McDonagh PF, Salel AF, Krohn KA, Rhode EA, Mason DT: Analysis of myocardial and total body integral extraction ratios of rubidium-86. Am J Physiol 235(6):H794-H802, 1978. PMID: 736167
  • Link JM, Grierson JR, Krohn KA: Alternatives in the synthesis of 2-[11C]-thymidine. J Label Comp Radiopharm 37:610-612, 1995
  • Krohn KA: The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images. Nucl Med Biol 28(5):477-483, 2001. PMID: 11516691
  • Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, Link JM, Krohn KA: Production of [F18]-fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 15:373-379, 2004. PMID: 15025534
  • Muzi M, Spence AM, O’Sullivan F, Mankoff DA, Wells JM, Grierson JR, Link JM, Krohn KA: Kinetic Analysis of 3’-deoxy-3’-18F-fluorothymidine in patients with gliomas. J Nucl Med 47:1612-1621, 2006. PMID: 17015896
  • Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA: [11C]Meta-hydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Annals Surg Oncol 13:187-197, 2006. PMID: 16418883
  • Krohn KA , Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. Jun;49 Suppl 2:129S-48S 2008. PMID: 18523070
  • Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. Epub 2011 Jul 12. PMID: 21750198
  • Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011 Aug 26. [Epub ahead of print] PMID: 21872957


  • {{[0].value }}